|
|
|
|
| LEADER |
02968nam a22004095i 4500 |
| 001 |
12425 |
| 003 |
DE-He213 |
| 005 |
20130215215653.0 |
| 007 |
cr nn 008mamaa |
| 008 |
120917s2013 xxu| s |||| 0|eng d |
| 020 |
# |
# |
|a 9781441997555
|9 978-1-4419-9755-5
|
| 024 |
7 |
# |
|a 10.1007/978-1-4419-9755-5
|2 doi
|
| 050 |
# |
4 |
|a RC254-282
|
| 072 |
# |
7 |
|a MJCL
|2 bicssc
|
| 072 |
# |
7 |
|a MED062000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.994
|2 23
|
| 100 |
1 |
# |
|a Lenz, Heinz-Josef.
|
| 245 |
1 |
0 |
|a Biomarkers in Oncology
|b Prediction and Prognosis /
|c edited by Heinz-Josef Lenz.
|h [electronic resource] :
|
| 260 |
# |
# |
|a New York, NY :
|b Springer New York :
|b Imprint: Springer,
|c 2013.
|
| 300 |
# |
# |
|a XVI, 447 p. 61 illus., 41 illus. in color.
|b digital.
|
| 505 |
0 |
# |
|a 1. Predictive Markers in Colon Cancer -- 2. Prognostic Markers in Breast Cancer -- 3. Predictive Markers in Lung Cancer -- 4. Prostate Cancer: Predictive Markers in Clinical Development -- 5. Biomarkers in GIST -- 6. Cytogenetic and Molecular Aberrations as Predictive Biomarkers in Acute Myeloid Leukemia -- 7. Prognostic Markers in Colon Cancer -- 8. Markers in Lung Cancer -- 9. Molecular Markers of Prostate Cancer Outcome -- 10. Prediction of Chemotherapy Toxicities -- 11. Surrogate Markers The Role of Positron Emission Tomography Scanning -- 12. Circulating Tumor Cells as Biomarkers -- 13. Focus on Personalized Molecular Based Medicine -- 14. Clinical Validation of Biomarkers -- 15. Regulatory Issues -- 16. Biomarkers for Safety Assessment and Clinical Pharmacology -- 17. Biomarker Discovery Strategies: DNA, RNA and Protein -- 18. Biomarkers For Go/No Go Decisions.
|
| 520 |
# |
# |
|a This integrated book covers the entire spectrum of cancer biomarkers in development and clinical use. Predictive and prognostic markers are explored in the context of colon cancer, breast cancer, lung cancer, prostate cancer, and GIST. International experts provide insight into toxicity markers and surrogate markers. Attention is also given to biomarker assay development, validation, and strategies. A powerful tool for determining decisions on therapy, selecting drug regimens, monitoring the efficacy of treatment, and performing individualized surveillance, biomarkers represent the forefront of cancer research and treatment. As these technologies become increasingly available for clinical use, this book will be an essential resource for oncologists and translational researchers.
|
| 650 |
# |
0 |
|a Medicine.
|
| 650 |
# |
0 |
|a Internal medicine.
|
| 650 |
# |
0 |
|a Biochemistry.
|
| 650 |
# |
0 |
|a Oncology.
|
| 650 |
1 |
4 |
|a Medicine & Public Health.
|
| 650 |
2 |
4 |
|a Oncology.
|
| 650 |
2 |
4 |
|a Internal Medicine.
|
| 650 |
2 |
4 |
|a Medical Biochemistry.
|
| 710 |
2 |
# |
|a SpringerLink (Online service)
|
| 773 |
0 |
# |
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9781441997548
|
| 856 |
4 |
0 |
|u https://ezaccess.library.uitm.edu.my/login?url=http://dx.doi.org/10.1007/978-1-4419-9755-5
|
| 912 |
# |
# |
|a ZDB-2-SME
|
| 950 |
# |
# |
|a Medicine (Springer-11650)
|